Article Text
Abstract
Background: S100A7 is a secreted protein and its overexpression has been previously associated with carcinogenesis of certain cancers. This study was undertaken to investigate the possibility that overexpression of S100A7 protein might be detected in the sera of patients with lung cancer.
Methods: RNA and protein levels of S100A7 were examined in 60 pairs of frozen lung cancer tissues by RT-PCR and western blot. The specific expression of this protein and its cellular distribution were investigated in 145 paraffin embedded lung cancer samples, six benign lung disease and 21 normal lung tissues by immunohistochemistry. The S100A7 protein level was further analysed in serum from 112 patients with lung cancer, 20 with benign lung diseases and 31 healthy individuals by ELISA.
Results: Specific expression of both S100A7 mRNA and protein was found in squamous cell carcinomas, adenosquamous carcinomas and large cell lung carcinomas, whereas neither was detected in adenocarcinomas or paired non-cancerous lung tissues. Further immunohistochemical analysis identified positive staining of S100A7 only in squamous cell carcinomas and large cell lung carcinomas, but not in other subtypes of lung cancer and normal lung tissues. Weak expression was also found in the inflammatory cells of benign lung diseases. Our most important finding is that elevated S100A7 protein could be detected in the sera of patients with squamous cell carcinomas.
Conclusion: S100A7 was only expressed in squamous cell carcinomas and large cell lung carcinomas and an increase in the level of S100A7 protein in serum may serve as a potential marker for lung cancer diagnosis.
Statistics from Altmetric.com
Footnotes
Funding: This work was supported in part by a Special Grant of the Major State Basic Research Program of China (No 2006CB910100), Project Supported by Natural Science Foundation of Beijing (No 7051002) and Project Supported by Science Technology Committee of Beijing (No Y0204002040111).
Competing interests: None.
Ethics approval: The study was approved by the Medical Ethics and Human Clinical Trial Committee at First Hospital of Jilin University and Cancer Hospital, Peking Union Medical College and Chinese Academy of Medical Science, as well as the General Hospital of Beijing Unit, PLA.